Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

HER-Vaxx is safe and provides clinical benefit over standard of care chemo for patients with HER2-overexpressing gastric cancer

ASCO GI 2023

19 - 21 Jan 2023

Published: 25 Jan 2023

Views: 160

Rating:

Save

Dr Tanuj Chawla and Dr Giovanni Selvaggi

Dr Tanuj Chawla and Dr Giovanni Selvaggi speak to ecancer as part of ASCO GI 2023 on the overall survival analysis of the HERIZON study.

The study evaluated the use of the HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma.

Dr Chawla and Dr Selvaggi explain the background of the trial before talking though the trial design.

Dr Chawla reports that the study was able to achieve 5 months better survival with the vaccine arm as compared to chemotherapy.

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS...

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

PD-1–refractory advanced melanoma: how do we get to the finish line?

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

$PD-1–refractory advanced melanoma: how do we get to the finish line? ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )$

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients...

Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR...

Dr Thierry André - Sorbonne Université, Paris, France

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC ( Dr Thierry André - Sorbonne Université, Paris, France )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Intra-arterial gemcitabine and IV gemcitabine/nab-paclitaxel show similar SAEs...

Dr Michael Pishvaian - Johns Hopkins Kimmel Cancer Center, Washington DC, USA

Intra-arterial gemcitabine and IV gemcitabine/nab-paclitaxel show similar SAEs in locally advanced pancreatic cancer ( Dr Michael Pishvaian - Johns Hopkins Kimmel Cancer Center, Washington DC, USA )

More from ecancer